Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 533

Sort by

Sort Order Select

Journal Articles

GPCR Promiscuity Reshapes Islet Physiology

Frans Schuit, Jonathan E. Campbell

Diabetes 2023;72(9):1180–1183

https://doi.org/10.2337/dbi23-0014

Published: 21 August 2023

View article titled, GPCR Promiscuity Reshapes Islet Physiology

Journal Articles

Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism

Sean M. Peterson, Christine A. Juliana, Cameron F. Hu, Jinghua Chai, Carson Holliday, Kara Y. Chan, Ana G. Lujan Hernandez, Zoe Challocombe, Linya Wang, Zhen Han, Nikhil Haas, Ryan Stafford, Fumiko Axelrod, Tom Z. Yuan, Diva D. De León, Aaron K. Sato

Diabetes 2023;72(9):1320–1329

https://doi.org/10.2337/db22-1039

Published: 26 June 2023

View article titled, Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism

Meeting Abstracts

1656-P: Glucagon-Like peptide-1 (GLP-1) Secretion from Intestinal L-Cells Is Mediated by hERG Potassium Channels

JIN-KUI YANG, CHANG LIU, HAO WANG, YINGCHAO YUAN

Diabetes 2023;72(Supplement_1):1656-P

https://doi.org/10.2337/db23-1656-P

Published: 20 June 2023

View article titled, 1656-P: Glucagon-Like peptide-1 (GLP-1) Secretion from Intestinal L-Cells Is Mediated by hERG Potassium Channels

Meeting Abstracts

1652-P: Suppression of Plasma Angiotensin II by GLP-1 in Humans Is Independent of Changes in Plasma Angiotensinogen

BOYE L. JENSEN, ALI ASMAR

Diabetes 2023;72(Supplement_1):1652-P

https://doi.org/10.2337/db23-1652-P

Published: 20 June 2023

View article titled, 1652-P: Suppression of Plasma Angiotensin II by GLP-1 in Humans Is Independent of Changes in Plasma Angiotensinogen

Meeting Abstracts

1612-P: Energetic Contributions of GLP1 and GCGR Activity in GLP1/GIP/GCGR Triagonism

SHELLY NASON, JESSICA ANTIPENKO, KIRK M. HABEGGER

Diabetes 2023;72(Supplement_1):1612-P

https://doi.org/10.2337/db23-1612-P

Published: 20 June 2023

View article titled, 1612-P: Energetic Contributions of GLP1 and GCGR Activity in GLP1/GIP/GCGR Triagonism

Meeting Abstracts

1006-P: Distributional Cost-Effectiveness Analysis of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) and Tirzepatide Compared with Sulfonylureas (SU) in People with Inadequately Controlled Type 2 Diabetes (T2D)

PIAOPIAO LI, DAWEI GUAN, MOHAMMED K. ALI, K.M. VENKAT NARAYAN, VIVIAN FONSECA, GUILLERMO UMPIERREZ, LIZHENG SHI, JIANG BIAN, YI GUO, ALMUT G. WINTERSTEIN, JINGCHUAN GUO, HUI SHAO

Diabetes 2023;72(Supplement_1):1006-P

https://doi.org/10.2337/db23-1006-P

Published: 20 June 2023

View article titled, 1006-P: Distributional Cost-Effectiveness Analysis of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) and Tirzepatide Compared with Sulfonylureas (SU) in People with Inadequately Controlled Type 2 Diabetes (T2D)

Meeting Abstracts

537-P: Virtual Patient Simulation Assesses the Levels of Competency and Improves Performance of Advance Practice Providers in the Field of Diabetes and Cardiometabolic Medicine

IGAL IANCU, RACHEL SHENTAL, LIRON ZEHAVI, BORIS DRAZNIN

Diabetes 2023;72(Supplement_1):537-P

https://doi.org/10.2337/db23-537-P

Published: 20 June 2023

View article titled, 537-P: Virtual Patient Simulation Assesses the Levels of Competency and Improves Performance of Advance Practice Providers in the Field of Diabetes and Cardiometabolic Medicine

Meeting Abstracts

103-LB: Impact of Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in COVID-19 Patients with Preexisting Type 2 Diabetes (T2D) and Cardiovascular Disease (CVD)

CHI NGUYEN, CHRISTOPHER L. CROWE, EFFIE KUTI, BONNIE M.K. DONATO, RACHEL L. DJARAHER, LEO J. SEMAN, NANCY GRAETER, THOMAS P. POWER, VINCENT WILLEY

Diabetes 2023;72(Supplement_1):103-LB

https://doi.org/10.2337/db23-103-LB

Published: 20 June 2023

View article titled, 103-LB: Impact of Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in COVID-19 Patients with Preexisting Type 2 Diabetes (T2D) and Cardiovascular Disease (CVD)

Meeting Abstracts

72-LB: DD01, a Novel Once-Weekly Dual GLP-1/Glucagon Receptor Agonist, Improves Metabolic Health and Achieves Rapid, Clinically Significant Reductions in Hepatic Steatosis following Only Four Weeks of Treatment and without the Need for Significant Weight Loss in Overweight/Diabetic Subjects with NAFLD

DENNIS TO, JAEHEE SHIN, SUBBU KARANTH, YEN-HUEI LIN, SVETLANA SOSNOVTSEVA, ADAM C. BELL

Diabetes 2023;72(Supplement_1):72-LB

https://doi.org/10.2337/db23-72-LB

Published: 20 June 2023

View article titled, 72-LB: DD01, a Novel Once-Weekly Dual GLP-1/Glucagon Receptor Agonist, Improves Metabolic Health and Achieves Rapid, Clinically Significant Reductions in Hepatic Steatosis following Only Four Weeks of Treatment and without the Need for Significant Weight Loss in Overweight/Diabetic Subjects with NAFLD

Meeting Abstracts

1378-P: Habitual High Sodium Intake Is Associated with Alterations in Glucose Homeostasis Including GLP-1 Secretion

ANNA DONKERS, HANNA HUBER, ALINA SCHIEREN, AAKASH MANTRI, WALDEMAR SEEL, BIRGIT STOFFEL-WAGNER, MARTIN COENEN, PETER KRAWITZ, JENS J. HOLST, PETER STEHLE, MARIE-CHRISTINE SIMON

Diabetes 2023;72(Supplement_1):1378-P

https://doi.org/10.2337/db23-1378-P

Published: 20 June 2023

View article titled, 1378-P: Habitual High Sodium Intake Is Associated with Alterations in Glucose Homeostasis Including GLP-1 Secretion

Meeting Abstracts

846-P: Risk of Anaphylaxis among New Users of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs)

MARY S. ANTHONY, LEILA DJEBARRI, DANIEL C. BEACHLER, VANITA R. ARODA, BRIAN CALINGAERT, CHUNSHEN PAN, CHRISTOPHER CROWE, STEPHAN LANES, KENNETH J. ROTHMAN, CATHERINE W. SALTUS, SOFIA BERREGHIS, LAUREN E. PARLETT, CLAIRE BOCAGE, KATHLEEN E. WALSH, JUHAERI JUHAERI, CATHERINE JOHANNES

Diabetes 2023;72(Supplement_1):846-P

https://doi.org/10.2337/db23-846-P

Published: 20 June 2023

View article titled, 846-P: Risk of Anaphylaxis among New Users of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs)

Meeting Abstracts

422-P: GLP-1 RA Should Be Used with SGLT2 Inhibitor in People with Rapidly Progressive CKD

KOJI KASHIMA, HIROYUKI SHIMIZU, MASANOBU YAMADA

Diabetes 2023;72(Supplement_1):422-P

https://doi.org/10.2337/db23-422-P

Published: 20 June 2023

View article titled, 422-P: GLP-1 RA Should Be Used with SGLT2 Inhibitor in People with Rapidly Progressive CKD

Meeting Abstracts

1300-P: Glucagon-Like Peptide-1 Levels Mirror Insulin Resistant States in Treatment-Naïve Type 2 Diabetes Mellitus

SHIAU CHIN CHONG, NORLELA SUKOR, SARAH A. ROBERT, KIM FONG NG, NOR A. KAMARUDDIN

Diabetes 2023;72(Supplement_1):1300-P

https://doi.org/10.2337/db23-1300-P

Published: 20 June 2023

View article titled, 1300-P: Glucagon-Like Peptide-1 Levels Mirror Insulin Resistant States in Treatment-Naïve Type 2 Diabetes Mellitus

Meeting Abstracts

1299-P: Predictors of Glucagon-Like Peptide-1 Responses following OGTT in Treatment-Naïve Type 2 Diabetes Mellitus among Three Ethnic Groups in Malaysia

SHIAU CHIN CHONG, NORLELA SUKOR, SARAH A. ROBERT, KIM FONG NG, NOR A. KAMARUDDIN

Diabetes 2023;72(Supplement_1):1299-P

https://doi.org/10.2337/db23-1299-P

Published: 20 June 2023

View article titled, 1299-P: Predictors of Glucagon-Like Peptide-1 Responses following OGTT in Treatment-Naïve Type 2 Diabetes Mellitus among Three Ethnic Groups in Malaysia

Meeting Abstracts

774-P: Weight-Independent Effects of CT-868, a Signaling Biased Dual GLP-1/GIP Receptor Modulator, on Glucose Homeostasis in Overweight and Obese Adults with Type 2 Diabetes

MANU CHAKRAVARTHY, MOISES HERNANDEZ, MICHAEL ELLIOTT, ALEJANDRA MACIAS, STIG K. HANSEN, MARCUS HOMPESCH

Diabetes 2023;72(Supplement_1):774-P

https://doi.org/10.2337/db23-774-P

Published: 20 June 2023

View article titled, 774-P: Weight-Independent Effects of CT-868, a Signaling Biased Dual GLP-1/GIP Receptor Modulator, on Glucose Homeostasis in Overweight and Obese Adults with Type 2 Diabetes

Meeting Abstracts

796-P: Real-World Persistence with GLP-1 RA Treatment in Patients with Type 2 Diabetes Mellitus (T2DM) and Advanced Chronic Kidney Disease (CKD)

FNU SIDRA, DONGLU XIE, SHUBHAM AGARWAL, ILDIKO LINGVAY

Diabetes 2023;72(Supplement_1):796-P

https://doi.org/10.2337/db23-796-P

Published: 20 June 2023

View article titled, 796-P: Real-World Persistence with GLP-1 RA Treatment in Patients with Type 2 Diabetes Mellitus (T2DM) and Advanced Chronic Kidney Disease (CKD)

Meeting Abstracts

609-P: Postprandial GLP-1 Response to Two Diabetes-Specific Formulas Compared with Instant Oatmeal in Adults With Type 2 Diabetes

SARA THOMAS, BETH BESECKER, YONG CHOE

Diabetes 2023;72(Supplement_1):609-P

https://doi.org/10.2337/db23-609-P

Published: 20 June 2023

View article titled, 609-P: Postprandial GLP-1 Response to Two Diabetes-Specific Formulas Compared with Instant Oatmeal in Adults With Type 2 Diabetes

Meeting Abstracts

201-LB: Benefit of Dual Therapy with GLP-1 RA and SGLT2i on Renal Outcomes in Type 2 Diabetes

BOCHRA ZAREINI, THOMAS A. GERDS, KATHRINE K. SØRENSEN, KIM K.B. CLEMMENSEN, KAJSA KVIST, JENS-PETER DAVID, CHRISTIAN TORP-PEDERSEN

Diabetes 2023;72(Supplement_1):201-LB

https://doi.org/10.2337/db23-201-LB

Published: 20 June 2023

View article titled, 201-LB: Benefit of Dual Therapy with GLP-1 RA and SGLT2i on Renal Outcomes in Type 2 Diabetes

Meeting Abstracts

200-LB: Benefit of Dual Therapy with GLP-1 RA and SGLT2i on Cardiovascular Outcomes in Type 2 Diabetes

BOCHRA ZAREINI, THOMAS A. GERDS, KATHRINE K. SØRENSEN, KIM K.B. CLEMMENSEN, KAJSA KVIST, JENS-PETER DAVID, CHRISTIAN TORP-PEDERSEN

Diabetes 2023;72(Supplement_1):200-LB

https://doi.org/10.2337/db23-200-LB

Published: 20 June 2023

View article titled, 200-LB: Benefit of Dual Therapy with GLP-1 RA and SGLT2i on Cardiovascular Outcomes in Type 2 Diabetes

Meeting Abstracts

313-OR: The Efficacy and Safety of Glucagon-Like-Peptide-1 Agonists in Patients with Familial Partial Lipodystrophy

SALMAN K. IMAM, MARIA C. FOSS-FREITAS, RASIMCAN MERAL, ELIF A. ORAL, ANABELA DILL GOMES, FATIHA GRISSI

Diabetes 2023;72(Supplement_1):313-OR

https://doi.org/10.2337/db23-313-OR

Published: 20 June 2023

View article titled, 313-OR: The Efficacy and Safety of Glucagon-Like-Peptide-1 Agonists in Patients with Familial Partial Lipodystrophy

NARROW

GPCR Promiscuity Reshapes Islet Physiology

Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism

1656-P: Glucagon-Like peptide-1 (GLP-1) Secretion from Intestinal L-Cells Is Mediated by hERG Potassium Channels

1652-P: Suppression of Plasma Angiotensin II by GLP-1 in Humans Is Independent of Changes in Plasma Angiotensinogen

1612-P: Energetic Contributions of GLP1 and GCGR Activity in GLP1/GIP/GCGR Triagonism

1006-P: Distributional Cost-Effectiveness Analysis of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) and Tirzepatide Compared with Sulfonylureas (SU) in People with Inadequately Controlled Type 2 Diabetes (T2D)

537-P: Virtual Patient Simulation Assesses the Levels of Competency and Improves Performance of Advance Practice Providers in the Field of Diabetes and Cardiometabolic Medicine

103-LB: Impact of Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in COVID-19 Patients with Preexisting Type 2 Diabetes (T2D) and Cardiovascular Disease (CVD)

1378-P: Habitual High Sodium Intake Is Associated with Alterations in Glucose Homeostasis Including GLP-1 Secretion

846-P: Risk of Anaphylaxis among New Users of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs)

422-P: GLP-1 RA Should Be Used with SGLT2 Inhibitor in People with Rapidly Progressive CKD

1300-P: Glucagon-Like Peptide-1 Levels Mirror Insulin Resistant States in Treatment-Naïve Type 2 Diabetes Mellitus

1299-P: Predictors of Glucagon-Like Peptide-1 Responses following OGTT in Treatment-Naïve Type 2 Diabetes Mellitus among Three Ethnic Groups in Malaysia

774-P: Weight-Independent Effects of CT-868, a Signaling Biased Dual GLP-1/GIP Receptor Modulator, on Glucose Homeostasis in Overweight and Obese Adults with Type 2 Diabetes

796-P: Real-World Persistence with GLP-1 RA Treatment in Patients with Type 2 Diabetes Mellitus (T2DM) and Advanced Chronic Kidney Disease (CKD)

609-P: Postprandial GLP-1 Response to Two Diabetes-Specific Formulas Compared with Instant Oatmeal in Adults With Type 2 Diabetes

201-LB: Benefit of Dual Therapy with GLP-1 RA and SGLT2i on Renal Outcomes in Type 2 Diabetes

200-LB: Benefit of Dual Therapy with GLP-1 RA and SGLT2i on Cardiovascular Outcomes in Type 2 Diabetes

313-OR: The Efficacy and Safety of Glucagon-Like-Peptide-1 Agonists in Patients with Familial Partial Lipodystrophy

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only